Autosomal Dominant Mendelian Susceptibility To Mycobacterial Diseases Due To Partial IFNgammaR1 Deficiency

1. Disease Information

1.1. Overview and Clinical Definition

Autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN‑γR1 deficiency is part of the broader group of Mendelian susceptibility to mycobacterial diseases (MSMD), an inborn error of immunity characterized by an inherited predisposition to severe infection by weakly virulent mycobacteria in individuals without overt abnormalities on routine immunologic screening.[7][8][11] MSMD as a syndrome is classified by the International Union of Immunological Societies (IUIS) among inborn errors of immunity affecting intrinsic and innate immunity, reflecting a disturbance in the IL‑12/IFN‑γ axis that is critical for host defense against intramacrophagic pathogens.[7][11][13] Within this syndrome, IFN‑γR1 deficiency was the first genetic etiology described in 1996, with biallelic null IFNGR1 mutations causing autosomal recessive complete IFN‑γR1 deficiency and revealing the essential roles of IFN‑γ signaling in human mycobacterial control.[3][7][8][14] Subsequent characterization of heterozygous IFNGR1 mutations established the autosomal dominant partial IFN‑γR1 deficiency variant (Immunodeficiency‑27B), in which receptor expression is preserved or increased but signaling is partially compromised.[4][6][8][12][16][18]

Clinically, autosomal dominant partial IFN‑γR1 deficiency (AD IFNGR1 deficiency, IMD27B) is defined by recurrent, moderately severe infections due to BCG and environmental non‑tuberculous mycobacteria, often presenting around early adolescence, with characteristic involvement of bone (unifocal or multifocal osteomyelitis), lymph nodes, and occasionally other organs.[4][6][12][16][18][19] Patients show residual IFN‑γ responses in vitro, such as partial STAT1 DNA‑binding (GAF activity) and induction of HLA class II molecules, underscoring the “partial” nature of the defect.[4][3][8] The immunodeficiency is generally not as severe as that seen in autosomal recessive complete IFN‑γR1 or IFN‑γR2 deficiencies, and many affected individuals have prolonged disease‑free intervals or respond well to antimycobacterial therapy.[4][6][8][14][16]

From a nosological standpoint, the disease is best conceptualized as a specific monogenic variant of MSMD with autosomal dominant inheritance and partial impairment of IFN‑γ receptor signaling, leading to selective susceptibility to low‑virulence mycobacteria and some other intramacrophagic pathogens while leaving many aspects of immunity intact.[7][8][10] It is distinct from other MSMD genotypes caused by defects in IL12RB1, IL12B, STAT1, TYK2, IRF8, and other genes in the IL‑12/IFN‑γ pathway, which may have overlapping but not identical clinical patterns.[7][8][13] The phenotype can be isolated (restricted to mycobacterial and related infections) or syndromic when accompanied by other infectious or inflammatory manifestations, though in AD IFNGR1 deficiency most reported patients have predominantly mycobacterial disease.[7][8][16][19]

1.2. Key Identifiers and Classification Codes

Autosomal dominant partial IFN‑γR1 deficiency is indexed under multiple genetic and disease ontologies. OMIM lists this condition as “Immunodeficiency‑27B, mycobacteriosis, autosomal dominant” under entry number 615978.[12][14] In OMIM, immunodeficiency‑27B is explicitly described as resulting from autosomal dominant IFNGR1 deficiency and as allelic to immunodeficiency‑27A (209950), the autosomal recessive complete IFN‑γR1 deficiency caused by biallelic IFNGR1 loss‑of‑function mutations.[12][14] Orphanet designates the disease as “Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial interferon gamma receptor 1 deficiency” and assigns it Orphanet ID 319581, highlighting its rarity (prevalence <1/1,000,000) and its classification within primary immunodeficiencies affecting IFN‑γ immunity.[4] MedGen recognizes the condition under the concept “Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,” corresponding to Concept ID C4014863, and synonymizes it with “IFNGR1 deficiency, autosomal dominant” and “Immunodeficiency 27B, mycobacteriosis, autosomal dominant.”[17][19]

At the gene level, IFNGR1 is catalogued under OMIM entry 107470 and HGNC approved symbol IFNGR1.[1][2][5] The receptor protein is also known as CD119 (Interferon‑γ receptor 1, IFN‑γR‑α chain), with UniProt accession P15260.[10] Cytogenetically, IFNGR1 maps to 6q23.3, and genomic coordinates on GRCh38 are approximately 6:137,197,484–137,219,385.[1][2] SNOMED CT codes associated with IFNGR1 and its deficiency include concepts related to generalized lymphadenopathy and osteomyelitis, reflecting typical phenotypic features.[18][19]

The disease falls into the MONDO ontology as “Autosomal dominant Mendelian susceptibility to mycobacterial disease due to partial IFN‑gamma receptor 1 deficiency,” corresponding to MONDO:0014429, although this identifier is referenced in the query rather than the provided search results. It would also be cross‑referenced under NCIT (NCI Thesaurus) as a primary immunodeficiency affecting IFN‑γ signaling, though the precise NCIT code is not explicit in the materials. From the perspective of ICD‑10/ICD‑11, patients are often coded under categories for primary immunodeficiencies and specific infections (e.g., osteomyelitis, atypical mycobacterial infection), as there is no dedicated ICD code for IFNGR1 deficiency itself; clinical coding focuses on the infectious manifestations rather than the molecular diagnosis.[4][6][11][13]

1.3. Synonyms and Alternative Names

Multiple synonymous names are used across resources and publications. OMIM and MedGen list “IFNGR1 deficiency, autosomal dominant,” “Immunodeficiency 27B, mycobacteriosis, autosomal dominant,” and “Immunodeficiency‑27B (IMD27B)” as standard labels.[12][14][17][19] Orphanet uses “Autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN‑gammaR1 deficiency,” emphasizing the MSMD framework and the partial nature of the defect.[4] Clinical reports frequently refer to “autosomal dominant partial IFN‑γR1 deficiency,” “dominant partial IFN‑γ receptor 1 deficiency,” or “AD MSMD due to IFN‑γR1 defect,” as in an Ethiopian case report where sequencing revealed a heterozygous IFNGR1 c.819_822del (p.Asn274Hisfs*2) variant.[11][16][19] In immunology and genetic literature, the condition is often discussed within the broader category of “IFN‑γR1 deficiencies” or “IFNGR1‑associated MSMD,” with specification of autosomal dominant partial versus autosomal recessive complete or partial forms.[3][7][8][16]

These synonyms reflect three conceptual axes: the gene affected (IFNGR1), the immunologic pathway (IFN‑γ receptor signaling), and the clinical syndrome (MSMD with mycobacteriosis). For ontology mapping, recommended disease‑level terms include MONDO “Mendelian susceptibility to mycobacterial disease” and subterm “autosomal dominant IFNGR1‑related MSMD,” as well as NCIT term “Primary immunodeficiency disorder” and HPO grouping term “Abnormality of the immune system.”[7][8][19]

1.4. Source of Information: Aggregated vs. Individual Data

The information available about autosomal dominant partial IFN‑γR1 deficiency is derived primarily from aggregated disease‑level resources and curated case series rather than raw electronic health records. OMIM, Orphanet, MedGen, and Gene‑centric databases such as NCBI Gene and HGNC compile data from published clinical case reports, multicenter cohorts, and mechanistic studies.[1][2][4][12][14][17][19] For example, an OMIM summary describes the clinical distinction between IMD27A (complete autosomal recessive IFNGR1 deficiency) and IMD27B (partial autosomal dominant IFNGR1 deficiency), citing the earlier onset and severity in the recessive form.[14] Orphanet’s characterization of age of onset, typical clinical features, and prevalence is based on aggregated study cohorts and expert review.[4]

Primary literature includes international series of MSMD patients in which subsets have IFN‑γR1 deficiency, such as global compilations reporting roughly 169 MSMD patients with IFNGR1 mutations (around 20.4% of all molecularly characterized MSMD cases).[8] Regional studies, for example, an Indian series of 50 MSMD patients with various genetic etiologies, identified 10 patients with IFN‑γR1 deficiency, although most of these had autosomal recessive complete deficiency rather than autosomal dominant partial forms.[13] Other publications are focused on specific IFNGR1 variants, such as the description of the common microdeletion 818del4, novel frameshift 774del4, or splice‑affecting missense p.Ile183Val, in cohorts of patients presenting with mycobacterial osteomyelitis and other manifestations.[15][16]

Overall, the disease description reflects a synthesis of human clinical data, functional immunologic assays, and genetic analyses, compiled at the disease level by expert consortia rather than derived from de‑identified EHR cohorts. There are no large population‑based registries dedicated exclusively to AD IFNGR1 deficiency, but MSMD registries and multicenter collaborations contribute to ongoing refinement of its natural history and clinical spectrum.[7][8][13][16]

2. Etiology

2.1. Primary Causal Factors: Genetic and Mechanistic Basis

The primary causal factor in autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN‑γR1 deficiency is a germline heterozygous mutation in the IFNGR1 gene, which encodes the ligand‑binding α chain of the human IFN‑γ receptor.[1][2][4][8][10] Human IFN‑γ receptor is a heterodimer composed of IFNGR1 (the ligand‑binding subunit) and IFNGR2 (the signal‑transducing accessory subunit); IFNGR1 is essential for high‑affinity binding of IFN‑γ, whereas IFNGR2 is primarily required for recruitment of JAK kinases and STAT1.[1][2][7][8][10] Dominant partial IFN‑γR1 deficiency arises when heterozygous IFNGR1 mutations give rise to truncated receptor molecules that are misregulated but still expressed at the cell surface, often in increased amounts, where they bind IFN‑γ but cannot transmit signals, thereby exerting a dominant‑negative effect over the wild‑type allele.[3][4][8][10][15][16]

Mutations causing AD partial IFN‑γR1 deficiency are clustered in the region encoding the cytoplasmic tail and recycling domain of the receptor, particularly exon 6.[4][8][15][16] The most common mutation reported is a microdeletion c.818del4, which creates a frameshift and premature stop codon, truncating the receptor in its extracellular domain and removing the intracellular segment that normally interacts with JAK1, JAK2, and STAT1.[4][8][15][16] Orphanet notes that microdeletion 818del4 is “by far the most common mutation,” corresponding to the first documented hotspot for a microdeletion in the human genome, and leads to expression of IFN‑γR1 on the cell surface but with no signal transduction.[4] Other recurrent variants include c.819_822del (p.Asn274Hisfs*2), described in Ethiopian and other patients, and c.774del4, a novel heterozygous frameshift reported in a Japanese girl with recurrent Mycobacterium avium osteomyelitis.[11][15][16][19] Truncating mutations such as 818del4, 819_822del, and 774del4 result in receptors lacking the intracellular domains required for JAK1 association, STAT1 docking, phosphorylation, and receptor degradation, producing stable, dominant‑negative molecules on the cell surface.[10][15][16]

The pathogenic mechanism is therefore a combination of partial loss‑of‑function and dominant‑negative interference. The truncated IFN‑γR1 molecule binds IFN‑γ but fails to recruit JAK1 and JAK2 kinases, preventing the phosphorylation of IFNGR1 and STAT1 and abrogating downstream transcriptional responses.[10][8][15] In addition, the truncated receptor lacks the motifs required for internalization and lysosomal degradation, leading to accumulation of mutant receptors at the cell surface and reduced turnover, which can sequester IFN‑γ and limit its binding to functional wild‑type receptors.[8][15][16] This explains the paradoxical observation that cells from AD partial IFN‑γR1‑deficient patients often display increased levels of IFN‑γR1 on their surfaces by flow cytometry, yet their functional responses to IFN‑γ are diminished.[4][8][15][16]

This etiology sharply contrasts with autosomal recessive complete IFN‑γR1 deficiency (IMD27A), in which biallelic IFNGR1 loss‑of‑function mutations lead to complete absence of cell surface receptor expression or expression of nonfunctional receptor with no residual IFN‑γ response.[3][6][8][14] It also differs from autosomal recessive partial IFN‑γR1 deficiency, where biallelic hypomorphic mutations allow partial signaling but without dominant‑negative accumulation of truncated receptor.[3][6][8] In AD partial IFN‑γR1 deficiency, the single mutant allele suffices to disrupt signaling due to the dominant‑negative effects of the truncated protein, while the wild‑type allele still produces a normal receptor that is partially functional but competitively disadvantaged.[3][4][8][15][16]

2.2. Genetic Risk Factors: Causal Variants and Susceptibility Loci

The principal genetic risk factors are heterozygous pathogenic variants in IFNGR1 that produce dominant partial receptor deficiency, with the best characterized being the exon 6 microdeletions and truncating variants.[4][8][15][16] As noted, c.818del4 is the most frequent mutation, reportedly a microdeletion hotspot in the human genome.[4][16] This variant has been described in multiple families across different geographic regions, including European and North American kindreds, and is associated with a relatively consistent phenotype of adolescent‑onset mycobacterial osteomyelitis and lymphadenopathy.[4][8][15][16] The c.819_822del (p.Asn274Hisfs*2) variant, closely related in position, was identified in an adolescent Ethiopian girl with repeated tuberculosis and non‑tuberculous mycobacterial infections involving lymph nodes, skin, bones, lungs, and epidural spaces.[11] Another frameshift, 774del4, has been reported in a Japanese girl with recurrent Mycobacterium avium osteomyelitis; this mutation produces a truncated receptor lacking intracellular domains and showing impaired degradation, similar to 818del4.[15]

The BJBMS study catalogued dominant partial IFN‑γR1 deficiency cases and found that all dominant disorders studied were associated with heterozygous low‑frequency variants c.819_822del, 818delT (a closely related deletion), or 832G>T (p.Glu278*), all producing truncated IFN‑γR1 proteins.[16] Most (79%) of dominant partial patients in that series had mycobacterial infections, and roughly one‑third had osteomyelitis of bone as the major manifestation.[16] The mean age of dominant partial deficiency patients was 13.4 years, and the penetrance of environmental mycobacterial disease was around 45% by age 10, indicating that not all mutation carriers become clinically symptomatic in childhood.[16] This incomplete penetrance underscores that heterozygous IFNGR1 mutations are necessary but not sufficient, with environmental exposures and potentially modifier genes influencing clinical expression.

In addition to frameshift truncations, a missense exonic splice variant IFNGR1:c.547A>G (p.Ile183Val) has been described in association with mycobacterial osteomyelitis.[16] This variant appears to affect splicing and perhaps surface expression of the receptor, representing the first missense exonic splice variant reported with dominant inheritance and MSMD phenotype.[16] In population databases, these pathogenic variants are extremely rare, with minor allele frequencies around 0.003% or lower, consistent with a prevalence of <1/1,000,000 for the clinical syndrome.[4][16] To date, no common susceptibility polymorphisms have been robustly implicated in AD IFNGR1 deficiency, although certain IFNGR1 variants have been associated with differential susceptibility to Helicobacter pylori infection, tuberculosis, and hepatitis B in broader population cohorts.[1] These latter associations likely represent complex trait contributions distinct from the monogenic AD partial deficiency considered here.

Beyond IFNGR1 itself, other genes in the IL‑12/IFN‑γ axis (e.g., IL12RB1, IL12B, STAT1, TYK2, IRF8, JAK1, CYBB) are causal for other forms of MSMD and may influence the clinical spectrum when co‑inherited, but there is no strong evidence that they act as modifier genes specific to AD partial IFN‑γR1 deficiency.[7][8][13] The current understanding is that heterozygous truncating IFNGR1 variants are the primary and necessary genetic risk factor for this disease, with variable penetrance determined largely by environmental exposure and perhaps stochastic events in immune development.[4][6][8][16]

2.3. Environmental Risk Factors and Triggers

Environmental risk factors are best conceptualized as infection‑related triggers rather than etiologic causes, as the underlying immunodeficiency is genetically determined. The principal environmental risk factor is exposure to weakly virulent mycobacteria, particularly BCG vaccine strains and environmental non‑tuberculous mycobacteria (NTM).[4][6][7][8][11][12][16][19] In countries where neonatal BCG vaccination is routine, infants and children with underlying IFN‑γR1 deficiency may develop disseminated BCG infection, although this is more typical for autosomal recessive complete or partial IFN‑γR1 deficiency; in autosomal dominant partial IFN‑γR1 deficiency, age of onset around adolescence implies that environmental mycobacteria and later exposures to BCG (e.g., revaccination or tuberculin testing in some settings) may be more relevant triggers.[4][6][14][16][18]

Environmental mycobacteria such as Mycobacterium avium, Mycobacterium bovis BCG, Mycobacterium abscessus, and related species are common pathogens in AD partial IFN‑γR1 deficiency, often causing unifocal or multifocal osteomyelitis and localized lymphadenitis.[4][6][8][12][16][18][19] The BJBMS study reported that 32% of dominant partial deficiency patients had mycobacterial infection of bone with no other organs apparently affected, suggesting that skeletal sites exposed to hematogenous spread or microtrauma may be particularly vulnerable.[16] High‑risk environmental exposures include contact with untreated water systems, soil, and aerosols harboring NTM, though specific environmental epidemiology has not been systematically characterized for this rare disease.[4][6][7][8]

Salmonella infection, especially Salmonella osteomyelitis, is an additional environmental trigger, reported in approximately 5% of patients with autosomal recessive or dominant IFNGR1 deficiency.[6][8][16][19] Other pathogens such as Histoplasma capsulatum and varicella‑zoster virus have been described in single patients with AD IFN‑γR1 deficiency, indicating occasional susceptibility to other intracellular organisms.[4][6] These infections often occur in geographic regions where the pathogens are endemic and where host exposure is common, further emphasizing the interaction between the genetic defect and environmental milieu.

Lifestyle, occupational exposures, and toxin exposures are not known to play a major etiologic role. There is no clear evidence that smoking, diet, or occupational environment modulate risk specifically in AD IFNGR1 deficiency, beyond the general influence of these factors on infection susceptibility and immune function. Age and sex appear to have relatively modest influence, with most reported patients presenting in childhood or adolescence and both sexes affected, though some series show a slight male preponderance typical of infections, which may reflect exposure differences or reporting bias.[4][6][8][13][16][19] Family history of recurrent mycobacterial infections is a strong risk indicator, consistent with autosomal dominant inheritance; genetic counseling can identify at‑risk relatives and inform vaccine choices, particularly regarding BCG.[4][6][14][18][19]

2.4. Protective Factors and Modifiers

Protective factors in AD partial IFN‑γR1 deficiency largely revolve around minimizing exposure to high‑risk pathogens and optimizing antimicrobial prophylaxis. Avoidance of BCG vaccination in individuals known to carry pathogenic IFNGR1 mutations is explicitly recommended by Orphanet and other expert sources, as BCG can cause local or disseminated disease in these patients.[4][6] For unaffected family members or individuals with uncertain carrier status, decisions about BCG should weigh tuberculosis risk against potential immunodeficiency, underscoring the importance of genetic screening in high‑risk families.[4][6][11]

Early recognition of the disease and prompt initiation of appropriate antimycobacterial therapy likely improves outcomes and reduces complications, functioning as a secondary protective factor.[4][6][8][11][16] In some patients, long‑term prophylactic antimycobacterial regimens (e.g., macrolides for Mycobacterium avium complex) may reduce recurrence, although data are limited. Recombinant IFN‑γ therapy has been employed as an adjunctive treatment in some MSMD patients, including those with IFN‑γ pathway defects, and may provide partial immunologic compensation when residual receptor function is present, as in AD partial IFN‑γR1 deficiency.[4][6][8][11]

Genetic protective variants specific to IFNGR1‑mediated MSMD have not been reported. Population genetic studies of IFNGR1 polymorphisms and susceptibility to tuberculosis or Helicobacter pylori suggest mild effects of common variants on infection risk, but these do not equate to protective alleles in the context of monogenic AD partial deficiency.[1] It is conceivable that co‑inheritance of stronger Th1 responses through other genes (e.g., IL12B, STAT4) could mitigate the clinical phenotype, but such modifier effects remain speculative and have not been substantiated in MSMD cohorts.[7][8][13]

2.5. Gene–Environment Interactions

Gene–environment interactions are central to the clinical expression of AD partial IFN‑γR1 deficiency. The heterozygous IFNGR1 mutation establishes a latent immunodeficiency that manifests clinically only upon exposure to specific pathogens—primarily weakly virulent mycobacteria—that rely heavily on IFN‑γ–driven macrophage activation for control.[4][6][7][8][16][19] In environments with low prevalence of BCG vaccination or environmental NTM exposure, some mutation carriers may remain asymptomatic, contributing to incomplete penetrance and age‑dependent expression.[4][6][16] Conversely, in regions with widespread BCG vaccination or high environmental mycobacterial burden, mutation carriers may present earlier and with more frequent disease episodes.[4][6][11][13]

The observed penetrance of around 45% by age 10 in dominant partial deficiency underscores that exposure timing, intensity, and pathogen strain influence whether and when disease manifests.[16] For example, a child with AD partial IFN‑γR1 deficiency living in an area with intensive BCG vaccination and high NTM presence in water systems is more likely to develop osteomyelitis or lymphadenitis than a counterpart living in a low‑exposure environment.[4][6][7][8] Meanwhile, co‑morbid conditions that alter immune function, such as malnutrition or HIV infection, could theoretically exacerbate susceptibility, although such interactions have not been systematically studied in IFNGR1‑related MSMD.[7][8][11][13]

From a mechanistic standpoint, the gene–environment interaction operates through the IL‑12/IFN‑γ axis: pathogen exposure stimulates IL‑12 production and IFN‑γ secretion by T cells and NK cells; in mutation carriers, IFN‑γ binding to IFN‑γR1 triggers only partial signaling, leading to suboptimal macrophage activation and bacterial killing, which allows clinical disease to develop.[7][8][10] GO biological process terms relevant to this interaction include “response to interferon‑gamma,” “regulation of macrophage activation,” and “defense response to bacterium,” while environmental exposure can be conceptualized via CHEBI terms for mycobacterial cell wall components and NCIT terms for “BCG vaccine” and “non‑tuberculous mycobacterial infection.” Integration of genetic and environmental data is important for risk stratification and preventive strategies in affected families.[4][6][13][16][19]

3. Phenotypes

3.1. Overall Clinical Phenotype Spectrum

Autosomal dominant partial IFN‑γR1 deficiency is characterized by a selective pattern of infectious phenotypes, dominated by recurrent mycobacterial infections and associated skeletal and lymphatic involvement.[4][6][8][12][16][18][19] The hallmark manifestations are recurrent, moderately severe infections with BCG and environmental mycobacteria, often presenting as unifocal or multifocal osteomyelitis, generalized lymphadenopathy, and occasionally disseminated or organ‑specific disease.[4][6][8][12][16][18][19] Many patients experience multiple episodes over years, reflecting persistent susceptibility despite partial immune function. Outside of these infections, general health may be relatively preserved, and routine immunologic parameters (e.g., immunoglobulin levels, lymphocyte counts) are often normal, consistent with a selective defect in IFN‑γ–mediated macrophage activation rather than global immune failure.[7][8][11][13]

Phenotypic variability is substantial, with severity ranging from isolated, intermittent osteomyelitis localized to a single bone to disseminated mycobacterial infection involving multiple organs.[4][6][8][16][19] Orphanet describes the typical phenotype as “recurrent, moderately severe infections with BCG and environmental mycobacteria,” with infections less severe than those seen in complete IFN‑γR1 or IFN‑γR2 deficiencies.[4] MedGen and OMIM highlight M. avium‑associated unifocal or multifocal osteomyelitis as a characteristic feature of AD IFN‑γR1 deficiency, distinguishing it clinically from other MSMD forms that more often present with disseminated lymphadenitis and visceral involvement.[12][18][19]

Additional infectious phenotypes include Salmonella infections, particularly Salmonella osteomyelitis, reported in about 5% of patients with autosomal recessive or dominant IFNGR1 deficiency.[6][8][16][19] In single patients, infections with Histoplasma capsulatum and varicella‑zoster virus have been documented, underscoring a broader, though still selective, susceptibility to certain intracellular pathogens.[4][6] In a large MSMD series, IFNGR1 mutations were associated not only with mycobacterial disease but also with infections due to Listeria monocytogenes, Salmonella spp., Streptococcus viridans, cytomegalovirus (CMV), HHV‑8, RSV, and other viruses, though these were more prominent in severe recessive forms.[8]

Phenotypic classification can be assisted by HPO terms. Key suggested HPO terms include “Recurrent mycobacterial infections,” “Osteomyelitis,” “Generalized lymphadenopathy,” “Recurrent salmonella infections,” and “Abnormality of the immune system.”[18][19] These map onto clinical signs (osteomyelitis, lymphadenopathy), infectious symptoms (fever, pain, localized swelling), and lab or imaging findings (radiographic bone lesions, positive mycobacterial cultures). The disease can be considered an “isolated MSMD” when restricted to mycobacterial infections or “syndromic MSMD” when accompanied by other infectious or inflammatory presentations.[7][8]

3.2. Recurrent Mycobacterial Infections

Recurrent mycobacterial infections are the defining symptom phenotype. Patients with AD partial IFN‑γR1 deficiency are prone to illness caused by moderately virulent mycobacterial species, such as BCG vaccine strains and environmental NTM, as well as occasional infections by more virulent Mycobacterium tuberculosis.[4][6][7][8][10][12][14][18][19] In Orphanet’s description, patients “present with moderately severe mycobacterial infections at around the age of 13 years,” which are recurrent but less severe than in complete receptor deficiencies.[4] Mendelian and OMIM summaries emphasize susceptibility to BCG and environmental mycobacteria (EM), with EM including species such as M. avium, M. abscessus, and related organisms.[6][8][12][14]

The clinical presentation of mycobacterial infection can vary. Osteomyelitis due to M. avium, M. bovis BCG, or other NTM often manifests as pain, swelling, and tenderness at affected bone sites, accompanied by radiographic lytic lesions or sclerotic changes.[4][6][8][12][16][18][19] Generalized or localized lymphadenopathy is common, with enlarged, sometimes necrotic lymph nodes, particularly in cervical, axillary, or inguinal regions.[4][18][19] In some patients, skin and soft tissue infections, pulmonary disease, or visceral involvement (liver, spleen) occur, especially in more severe or untreated cases.[4][6][8][11][13]

Age of onset is typically adolescent, with Orphanet citing an average onset around 13 years, in contrast to the mean age of 1.3 years for autosomal recessive complete IFN‑γR1 deficiency.[4][6][14][16][18] However, earlier onset in childhood is possible, particularly in settings with early BCG vaccination and high pathogen exposure, as illustrated by case reports of children presenting with multiple mycobacterial infections from infancy onward.[11][13] Symptom severity is moderate to severe but generally less catastrophic than in recessive complete deficiency; life‑threatening disseminated disease is less frequent, and many patients respond to therapy and survive into adulthood.[4][6][8][14][16][18] The course is often relapsing‑remitting, with episodes of infection separated by periods of relative health, though chronic osteomyelitis may lead to lasting structural damage and functional impairment.[4][6][8][16][19]

Quality of life impact is significant for those with recurrent infections and bone involvement. Chronic pain, decreased mobility, need for repeated surgeries, prolonged antimicrobial regimens, and hospitalizations can impair schooling, work, and psychosocial well‑being.[4][6][11][16][19] HPO terms such as “Pain,” “Impaired mobility,” and “Chronic infection” capture these impacts, while EQ‑5D and SF‑36 domains related to physical functioning, bodily pain, and role limitations are pertinent for formal assessment.[11] Nonetheless, many patients have relatively normal lives between episodes, and those with milder phenotypes or partial penetrance may experience only isolated events with limited long‑term disability.[4][6][8][16]

3.3. Osteomyelitis and Bone Involvement

Osteomyelitis is the prototypical organ‑specific manifestation of AD partial IFN‑γR1 deficiency. In Orphanet and MedGen descriptions, infections with M. bovis BCG or M. avium often lead to unifocal or multifocal osteomyelitis, typically in long bones, vertebrae, or other skeletal sites.[4][12][18][19] The BJBMS study noted that 32% of dominant partial IFN‑γR1‑deficient patients had mycobacterial infection confined to bone with no other organs affected, and that one‑third of all dominant partial patients had osteomyelitis as a major component.[16] OMIM underscores that in AD IFNGR1 deficiency, M. avium infection tends to cause unifocal or multifocal osteomyelitis, highlighting this as a distinguishing feature.[12][18]

Clinically, osteomyelitis presents with localized bone pain, swelling, erythema, and sometimes systemic symptoms such as fever and malaise. Radiographs and MRI reveal lytic lesions, periosteal reaction, and sometimes sequestra or sclerosis, depending on chronicity.[11][15][16] Histologic examination of bone biopsies shows granulomatous inflammation, occasionally caseating necrosis, and acid‑fast bacilli detectable by Ziehl–Neelsen staining.[11][13][15][16] Microbiologic cultures or molecular tests (e.g., mycobacterial rRNA amplification, GeneXpert) often identify specific mycobacterial species; in some series, amplified nucleic acid tests detected mycobacterial rRNA in biopsies, confirming infection by BCG or environmental mycobacteria.[15][16]

Age at onset of osteomyelitis in AD partial IFN‑γR1 deficiency corresponds to overall disease onset (often adolescence), and progression may be chronic if inadequately treated.[4][6][16][18] Recurrence is common, with new bone sites involved over time or persistent disease at the same site despite therapy.[15][16][19] Osteomyelitis may be multifocal, affecting multiple bones simultaneously or sequentially; such multifocal involvement can cause substantial morbidity, including fractures, deformities, and functional limitations.[4][6][11][15][16] Quality of life impact is marked, with HPO terms “Osteomyelitis,” “Bone pain,” and “Skeletal deformities” capturing clinical features, and EQ‑5D dimensions “Mobility” and “Pain/discomfort” particularly relevant.[11]

3.4. Generalized Lymphadenopathy and Other Signs

Generalized lymphadenopathy is a frequent sign, reflecting immune activation and granulomatous response to mycobacteria. MedGen lists “Generalized lymphadenopathy” (Concept ID C0476486) as a clinical feature of AD IFN‑γR1 deficiency, citing SNOMED CT terms such as “Generalized lymph node enlargement” and HPO term “Generalized lymphadenopathy.”[18][19] Lymph nodes may be enlarged, firm, sometimes tender, and occasionally suppurative, with histology showing granulomatous inflammation and acid‑fast bacilli in cases of active mycobacterial infection.[11][13][16] Lymphadenopathy may co‑occur with osteomyelitis or other organ involvement, or appear as the initial presentation of MSMD.[7][8][11][13]

Other clinical signs include fever, weight loss, malaise, and night sweats during active infection episodes. Skin manifestations, such as nodules or ulcers overlying bone lesions or lymph nodes, may occur, reflecting extension of granulomatous inflammation.[11][13][16] Pulmonary disease, including nodular infiltrates or cavitary lesions due to NTM or M. tuberculosis, can be part of the phenotype, especially in individuals with high exposure or delayed diagnosis.[7][8][11][13] Visceral involvement (liver, spleen, bone marrow) with granulomas has been reported predominantly in more severe IFNGR1 deficiencies, but may occasionally appear in AD partial forms.[8][13][16]

Age of onset for these signs mirrors infection onset, with variable severity and progression. Some patients experience acute episodes with rapid symptom onset and antibiotic‑responsive disease; others develop insidious, chronic signs with slow progression of lymphadenopathy and osteomyelitis.[4][6][11][13][16] Quality of life impact includes fatigue, decreased exercise tolerance, and psychological stress associated with chronic illness. HPO terms such as “Fever,” “Weight loss,” and “Fatigue” are relevant, and SF‑36 domains of vitality and mental health can capture broader effects.[11]

3.5. Laboratory and Immunologic Phenotypes

Laboratory abnormalities in AD partial IFN‑γR1 deficiency primarily reflect functional immunologic defects rather than quantitative deficits. Routine blood counts and immunoglobulin levels are often normal, distinguishing MSMD from many other primary immunodeficiencies.[7][8][11][13] Specific immunologic assays, however, reveal impaired IFN‑γ responses. Cells from affected patients show increased IFN‑γR1 expression on the cell surface by flow cytometry, due to accumulation of truncated receptors, but exhibit diminished STAT1 phosphorylation and downstream gene induction upon IFN‑γ stimulation.[4][8][10][15][16]

Orphanet notes that patient cells show a residual response to IFN‑γ in terms of STAT1 DNA‑binding (GAS‑binding activity) and HLA class II induction, confirming partial deficiency.[4] The Abcam IFNGR1 entry explains that upon ligand binding, the intracellular domain of IFNGR1 normally allows association of downstream signaling components JAK1 and JAK2; activated JAK1 phosphorylates IFNGR1 to create a docking site for STAT1, whose subsequent phosphorylation leads to dimerization, nuclear translocation, and target gene transcription.[10] In AD partial IFN‑γR1 deficiency, truncation and misregulation of the intracellular domain impair these steps, resulting in reduced STAT1 activation, decreased “gamma‑activated factor” (GAF) binding to GAS elements in DNA, and attenuated transcription of IFN‑γ‑responsive genes.[8][10][15][16]

Functional testing may include measurement of STAT1 phosphorylation (by flow cytometry or Western blot) after IFN‑γ stimulation, assessment of HLA class II upregulation, and evaluation of induction of genes such as IRF1 or CXCL9. These tests reveal partial but not absent responses in AD IFN‑γR1 deficiency, differentiating it from complete deficiencies.[4][8][10][16] Standard immunological phenotyping often shows normal T‑ and B‑cell numbers, normal NK cell counts, and normal serum immunoglobulins, but skewed Th1 responses in functional assays.[7][8][11][13]

Suggested HPO terms for the immunologic phenotype include “Abnormal interferon‑gamma response,” “Abnormal cellular immunity,” and “Abnormality of the immune system.” GO biological process terms relevant to the functional defect include “response to interferon‑gamma,” “JAK–STAT cascade,” and “macrophage activation.” CL ontology terms encompass “macrophage,” “monocyte,” “natural killer cell,” and “CD4+ T cell,” as these are key cell populations affected by impaired IFN‑γ signaling.[7][8][10]

4. Genetic and Molecular Information

4.1. Causal Gene: IFNGR1

IFNGR1 (interferon gamma receptor 1) is the sole causal gene for autosomal dominant partial IFN‑γR1 deficiency (IMD27B). NCBI Gene describes IFNGR1 as encoding the ligand‑binding chain (α chain) of the IFN‑γ receptor, which together with IFNGR2 forms the functional receptor.[2] OMIM entry 107470 similarly identifies IFNGR1 as the gene for the IFN‑γ receptor 1, noting its role in binding IFN‑γ and its mapping to chromosome 6q23.3.[1] Early mapping by Aguet et al. used radiation hybrid analysis to localize IFNGR1 to chromosome 6q, while in situ hybridization regionalized it further to 6q23‑q24.[1] Southern blot analysis suggested that IFNGR1 is a single‑copy gene, supporting its straightforward genetic interpretation.[1]

At the protein level, IFN‑γR1 is a type I single‑pass transmembrane glycoprotein belonging to the type II cytokine receptor family.[10] It consists of an extracellular domain that binds IFN‑γ, a transmembrane segment, and an intracellular domain that interacts with JAK1 and other signaling molecules.[10] Upon ligand binding, conformational changes allow association with IFNGR2 and the JAK1/JAK2 kinases, leading to phosphorylation events that recruit STAT1.[10] Downstream STAT1 dimerization and nuclear translocation activate transcription of interferon‑stimulated genes essential for macrophage activation, antigen presentation, and cellular immunity.[7][8][10]

IFNGR1 is implicated not only in monogenic MSMD but also in complex susceptibility to infectious diseases. OMIM notes associations between IFNGR1 variation and susceptibility to Helicobacter pylori infection, hepatitis B virus infection, and tuberculosis, as well as protection against or susceptibility to tuberculosis infection in different genetic contexts.[1] However, these complex traits likely involve common polymorphisms with modest effects, distinct from the rare, high‑penetrance truncating mutations responsible for autosomal dominant partial IFN‑γR1 deficiency.[1][6][7][8]

4.2. Pathogenic Variant Types and Functional Consequences

Pathogenic variants in AD partial IFN‑γR1 deficiency are predominantly frameshift truncating mutations, clustered in exon 6 and producing prematurely terminated receptors lacking the intracellular signaling domain.[4][8][15][16] The microdeletion 818del4 and closely related c.819_822del represent the best characterized variants, described as a “hotspot” for microdeletion in the human genome.[4][16] These deletions shift the reading frame and introduce early stop codons, resulting in truncated proteins that fail to associate with JAK1 and JAK2 and cannot be phosphorylated at key residues, such as Tyr‑457, required for IFN‑γ receptor signal transduction.[10][15][16]

The Blood article describing 774del4 mutation demonstrated that this heterozygous frameshift produces a truncated protein lacking the intracellular component of IFN‑γR1.[15] In functional studies, cells expressing the 774del4 mutant protein showed stable retention of the receptor on the cell surface after cycloheximide treatment, in contrast to wild‑type IFN‑γR1, which is rapidly degraded.[15] This supported the conclusion that 774del4, like 818del4, causes overexpression of dominant‑negative IFN‑γR1 on the cell surface through impairment of receptor degradation.[15] The BJBMS review similarly notes that dominant partial deficiency cases involve truncated proteins lacking intracellular domains, JAK1 binding sites, and degradation signals, leading to accumulation of mutant receptors.[16]

From a functional standpoint, these mutations produce a dominant‑negative effect. Mutant receptors can form complexes with IFN‑γ and IFNGR2 but cannot initiate proper JAK–STAT signaling, meaning that they compete with wild‑type receptors for ligand and receptor complex formation.[8][10][15][16] This competition reduces the effective signaling capacity even though one allele remains wild‑type, explaining why heterozygous truncations behave as dominant defects rather than simple haploinsufficiencies.[8][16] Residual signaling is present, as evidenced by partial STAT1 activation and HLA class II induction in patient cells, but is insufficient to fully control mycobacterial infections.[4][8][10]

Variant classification according to ACMG/AMP guidelines would categorize these truncating exon 6 mutations as pathogenic, given the strong evidence from functional studies, segregation with disease, absence or extreme rarity in population databases, and established mechanism of dominant partial receptor deficiency.[4][8][15][16] Missense splice variants such as p.Ile183Val would also be considered likely pathogenic or pathogenic, based on association with disease, functional evidence of splicing alteration, and absence from controls.[16] Somatic IFNGR1 variants are not implicated in this disease; the causative mutations are germline and present in all cells. No large structural variants or chromosomal rearrangements involving IFNGR1 have been reported as causal in AD partial deficiency, though rare microdeletions could theoretically encompass part of the gene.[1][4][8][14][16]

4.3. Population Frequencies and Founder Effects

Given the disease’s rarity (prevalence <1/1,000,000), pathogenic IFNGR1 variants underlying AD partial IFN‑γR1 deficiency are expectedly rare in population genomic databases such as gnomAD, ExAC, and TOPMed.[4][16] The BJBMS review notes that heterozygous low‑frequency variants like c.819_822del, 818delT, and 832G>T have minor allele frequencies around 0.003%, consistent with their identification in a small number of families.[16] The microdeletion 818del4 is described as a mutational hotspot, suggesting recurrent origin rather than a single founder event, although in specific populations founder effects may exist where the same variant is present in multiple related families.[4][16]

Geographically, AD partial IFN‑γR1 deficiency cases have been reported across diverse populations, including European (e.g., French, Polish), Japanese, Ethiopian, and other origins.[3][11][15][16] The Ethiopian case of c.819_822del, the Japanese case of 774del4, and European series with 818del4 illustrate the global distribution of these mutations.[11][15][16] While local founder effects may be present (e.g., multiple individuals in one region harboring the same mutation), overall the disease does not appear confined to a single ethnic group and likely occurs sporadically worldwide at very low frequency.[4][6][8][13][16]

Carrier frequency for specific mutations is not systematically quantified but would approximate the reported allele frequencies (on the order of 1 in tens of thousands), aligning with the disease’s rarity and incomplete penetrance.[4][16] As autosomal dominant inheritance with partial penetrance implies that not all carriers manifest clinically, the number of genetic carriers may exceed the number of diagnosed patients, particularly in settings with limited access to advanced immunologic and genetic diagnostics.[4][6][8][13][16][19]

4.4. Epigenetic and Regulatory Aspects

Current evidence does not implicate epigenetic alterations (DNA methylation, histone modification, chromatin remodeling) as primary drivers of AD partial IFN‑γR1 deficiency. The disease is defined by coding mutations in IFNGR1, and there are no reports of regulatory region mutations or epigenetic dysregulation causing clinically similar phenotypes.[4][6][8][16] However, IFNGR1 expression and IFN‑γ signaling are subject to normal epigenetic regulation in immune cells, and changes in chromatin accessibility at interferon‑stimulated gene loci can modulate responsiveness to IFN‑γ.[7][8][10]

For example, STAT1 binding to GAS elements in promoters of IFN‑γ‑responsive genes recruits co‑activators and histone acetyltransferases, leading to increased chromatin accessibility and transcription.[7][8][10] In AD partial IFN‑γR1 deficiency, reduced STAT1 activation likely results in attenuated epigenetic remodeling at these loci, though this is a downstream consequence of receptor mutation rather than a primary cause. GO terms such as “chromatin organization,” “histone modification,” and “regulation of transcription in response to interferon‑gamma” are relevant to these secondary epigenetic effects.[7][8][10]

Large consortia such as ENCODE and Roadmap Epigenomics characterize IFNGR1 regulatory elements in normal immune cells, but disease‑specific epigenomic profiling of IFNGR1‑deficient patients has not been reported. Thus, at present, epigenetic information does not play a central role in etiologic understanding, and the disease can be regarded as a classic monogenic receptor defect with primarily genetic rather than epigenetic causation.[4][6][8][16]

4.5. Molecular Signaling Pathways

The key molecular pathway affected is the IFN‑γ–induced JAK–STAT signaling cascade. IFN‑γ binds to pre‑assembled IFN‑γ receptor complexes comprising IFNGR1 and IFNGR2 on cell surfaces.[7][8][10] The intracellular domain of IFNGR1 associates with JAK1, while IFNGR2 associates with JAK2.[10] Upon ligand binding, conformational changes allow JAK1 and JAK2 activation and phosphorylation of IFNGR1, creating docking sites for STAT1.[10] STAT1 is then phosphorylated, dimerizes, translocates to the nucleus, and binds to gamma‑activated sequence (GAS) elements in target gene promoters, driving transcription of interferon‑stimulated genes involved in antimicrobial activity, antigen presentation, and immunomodulation.[7][8][10]

Abcam’s functional description emphasizes that phosphorylation of Tyr‑457 on IFNGR1 is required for signal transduction and that IFNGR1 intracellular domain phosphorylation also provides a docking site for SOCS1, which regulates the JAK–STAT pathway by competing with STAT1 binding.[10] Ubiquitination of IFNGR1 after phosphorylation in a CSNK1A1‑dependent manner leads to lysosome‑dependent degradation, regulating receptor turnover.[10] In AD partial IFN‑γR1 deficiency, truncating mutations in IFNGR1’s intracellular domain disrupt Tyr‑457 phosphorylation, impair STAT1 docking, and alter SOCS1 and ubiquitination pathways, leading to defective signaling and abnormal receptor degradation.[8][10][15][16]

GO pathway terms such as “JAK–STAT cascade,” “response to interferon‑gamma,” “cytokine‑mediated signaling pathway,” and “regulation of immune effector process” capture the molecular processes involved.[7][8][10] Reactome and KEGG pathways for IFN‑γ signaling similarly map IFNGR1 to upstream receptor activation events and STAT1 to downstream transcriptional responses. Disruption of these pathways in macrophages, dendritic cells, T cells, and NK cells underlies the immunodeficiency phenotype.[7][8][10]

5. Environmental and Infectious Information

5.1. Environmental Factors and Lifestyle

As discussed in the etiology section, non‑genetic environmental factors primarily concern pathogen exposure rather than toxins, radiation, or lifestyle in the traditional sense. There is no evidence that chemical toxins, pollution, or occupational exposures directly cause or significantly modulate AD partial IFN‑γR1 deficiency, aside from their general impact on infection risk.[4][6][7][8] Lifestyle factors such as smoking, diet, and exercise do not appear to specifically alter the disease course, although overall health status and nutritional adequacy may influence resilience to infections.[7][8][11][13]

Education about avoiding high‑risk exposures to environmental mycobacteria (e.g., poorly maintained hot tubs, untreated water sources) may be beneficial in reducing infection risk, but practical guidelines tailored to IFNGR1 deficiency are not yet formalized.[4][6][8] In regions with high tuberculosis prevalence, adherence to public health measures such as TB screening and appropriate chemoprophylaxis is advisable, although TB susceptibility in AD partial IFN‑γR1 deficiency appears less pronounced than in complete receptor deficiencies.[6][7][8][14]

5.2. Infectious Agents and Pathogen Spectrum

The most important environmental component is the spectrum of infectious agents to which patients are uniquely susceptible. The MSMD literature divides mycobacterial agents into weakly virulent (e.g., BCG vaccine strains and environmental NTM) and more virulent (e.g., M. tuberculosis), with MSMD patients particularly prone to disease from the former.[7][8] Over the last 20 years, 19 genes have been found mutated in MSMD patients, but IFNGR1 is the archetypal gene for this susceptibility.[7][8]

In AD partial IFN‑γR1 deficiency, the principal pathogens are BCG and environmental mycobacteria, especially M. avium.[4][6][8][12][14][16][18][19] Mycobacterium bovis BCG vaccines, given intradermally at birth in many countries, can cause local or disseminated infection in patients with IFN‑γ pathway defects; in AD partial deficiency, BCG infections are recurrent and moderately severe, often manifesting as osteomyelitis or lymphadenitis rather than fulminant disseminated disease.[4][6][7][8][14][16] Environmental NTM (EM), including M. avium complex, M. abscessus, M. fortuitum, and related species, are prevalent in water, soil, and aerosols and cause bone and soft tissue infections in these patients.[4][6][8][12][16][18][19]

Other intramacrophagic pathogens associated with IFNGR1 deficiency include Salmonella species, particularly in the form of osteomyelitis; Histoplasma capsulatum, a dimorphic fungus causing histoplasmosis; and certain viruses such as varicella‑zoster virus, CMV, and HHV‑8, though these are more widely reported in complete IFN‑γR1 deficiency.[4][6][8][16] The IFNGR1 summary in a comprehensive MSMD review lists pathogens encountered in IFNGR1‑mutant patients: BCG; multiple NTM species (M. chelonae, M. fortuitum, M. margaritense, M. smegmatis, M. scrofulaceum, M. abscessus, M. szulgai, M. asiaticum, M. gordonae, M. kansasii); viruses (CMV, HHV‑8, RSV, PRV‑3, VZV); and bacteria (Listeria monocytogenes, Salmonella spp., Streptococcus viridans).[8] However, most of these severe infections have occurred in autosomal recessive complete or partial IFN‑γR1 deficiency; AD partial deficiency patients generally exhibit a narrower spectrum dominated by mycobacteria and occasional Salmonella.[4][6][8][12][16][19]

NCBI Taxonomy identifiers would map to species such as Mycobacterium avium (NCBI Taxon ID 1764), Mycobacterium bovis (Taxon ID 1765), Salmonella enterica (Taxon ID 28901), and Histoplasma capsulatum (Taxon ID 5037). NCIT intervention terms relevant to infection management include “Antimycobacterial Therapy,” “Antibiotic Therapy,” and “Antifungal Therapy.”

5.3. Gene–Environment–Pathogen Triad

The interaction among the IFNGR1 mutation, environmental exposures, and pathogen characteristics shapes the observed clinical phenotype. Weakly virulent mycobacteria rely heavily on IFN‑γ–activated macrophage effector functions (e.g., inducible nitric oxide synthase, phagolysosome maturation) for control.[7][8][10] In AD partial IFN‑γR1 deficiency, these effector functions are only partially induced, allowing persistent infection and local tissue damage despite some residual immunity.[4][6][8][10][16] More virulent pathogens such as M. tuberculosis may be somewhat controlled by residual IFN‑γ signaling and other immune pathways, contributing to a milder TB susceptibility compared to complete IFN‑γR1 deficiency.[6][7][8][14]

The severity and localization of disease may also depend on tissue‑specific immune microenvironments and pathogen tropism. Bone and lymph nodes may be particularly susceptible due to high macrophage content and slow local clearance of mycobacteria.[4][6][8][16][19] Pathogen factors such as cell wall composition, replication rate, and ability to evade immune recognition also modulate clinical severity. This triad underscores the need for integrated understanding of host genetics, environment, and pathogen biology in MSMD and related disorders.[7][8][13][16]

6. Mechanism and Pathophysiology

6.1. Ordered Causal Chain from Mutation to Clinical Manifestation

1. A germline heterozygous truncating mutation in IFNGR1 (e.g., c.818del4, c.819_822del, c.774del4) leads to production of a truncated IFN‑γR1 receptor lacking critical intracellular signaling and recycling domains.[4][8][15][16]

2. The truncated IFN‑γR1 is still expressed at the cell surface, often at increased levels due to impaired ubiquitination and lysosomal degradation, and binds IFN‑γ but cannot properly recruit JAK1 and JAK2 or be phosphorylated at key tyrosine residues (e.g., Tyr‑457).[10][15][16]

3. The mutant receptor competes with wild‑type IFN‑γR1 for ligand and receptor complex formation, exerting a dominant‑negative effect that reduces overall IFN‑γ signal transduction through the JAK–STAT1 pathway (partially inferred from functional studies).[3][4][8][10][15][16]

4. Reduced STAT1 phosphorylation and nuclear translocation result in attenuated transcriptional activation of IFN‑γ–responsive genes in macrophages, dendritic cells, T cells, and NK cells, including genes involved in antimicrobial effector functions, antigen presentation, and Th1 differentiation.[7][8][10]

5. Macrophages and other phagocytes exhibit impaired activation, with diminished production of reactive nitrogen intermediates, defective phagolysosome maturation, and suboptimal killing of intracellular mycobacteria and certain other pathogens (inferred from MSMD models and IFN‑γ biology).[7][8][10]

6. Persistent survival and replication of weakly virulent mycobacteria, especially BCG and environmental NTM, occur within macrophages in bone, lymph nodes, and other tissues, leading to chronic granulomatous inflammation and localized tissue damage.[4][6][7][8][12][16][18][19]

7. In bone, granulomatous inflammation and osteoclastic activity result in osteomyelitis with lytic lesions, periosteal reaction, and structural compromise; in lymph nodes, similar processes cause lymphadenopathy and potential suppuration.[4][6][8][12][16][18][19]

8. Incomplete but present IFN‑γ signaling allows partial containment of infection, preventing the fulminant disseminated disease typical of complete IFN‑γR1 deficiency, leading instead to recurrent, moderately severe localized infections and relapsing course.[4][6][8][14][16][18]

9. Chronic inflammation and recurrent infection episodes cause cumulative morbidity (bone deformities, chronic pain, functional impairment) and require prolonged antimicrobial therapy and occasional surgical intervention.[4][6][11][15][16][19]

10. The overall clinical phenotype of adolescent‑onset, recurrent mycobacterial osteomyelitis and lymphadenopathy in an otherwise immunologically normal host emerges from this chain of events, defining autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN‑γR1 deficiency.[4][6][8][12][16][18][19]

6.2. Molecular Pathways: IFN‑γ–JAK–STAT Axis

At the molecular level, the central pathway disrupted is the IFN‑γ–induced JAK–STAT signaling cascade. IFN‑γ is produced by activated T cells and NK cells in response to IL‑12 and antigen stimulation.[7][8] It binds to IFN‑γ receptors on macrophages, dendritic cells, and other cell types, initiating intracellular signaling. IFN‑γR1 serves as the ligand‑binding component, while IFN‑γR2 acts as the accessory chain necessary for signal transduction.[1][2][7][8][10]

In normal cells, IFN‑γ binding induces conformational changes that bring JAK1 (associated with IFN‑γR1) and JAK2 (associated with IFN‑γR2) into proximity, leading to trans‑phosphorylation and activation.[10] Activated JAK1 phosphorylates specific tyrosine residues on IFN‑γR1, notably Tyr‑457, creating docking sites for STAT1.[10] STAT1 is subsequently phosphorylated, dimerizes, and moves to the nucleus, where it binds GAS motifs in promoters of interferon‑stimulated genes, inducing transcription.[7][8][10] These genes include IRF1, CXCL9, CXCL10, HLA‑DR, and other components involved in antigen presentation, chemokine production, and antimicrobial effector mechanisms.[7][8][10]

SOCS1 and other negative regulators modulate the pathway by binding to phosphorylated IFN‑γR1 and JAK kinases to terminate signaling, while ubiquitination and lysosomal degradation of the receptor control its turnover.[10] In AD partial IFN‑γR1 deficiency, truncation of the intracellular domain eliminates key phosphorylation sites and docking motifs, preventing STAT1 recruitment and disrupting SOCS1‑mediated feedback.[8][10][15][16] Abnormal receptor degradation further causes surface accumulation of mutant IFN‑γR1.[10][15][16] The overall effect is reduced amplitude and duration of IFN‑γ–induced gene expression, particularly in macrophages and related cells. GO terms such as “response to interferon‑gamma,” “JAK–STAT cascade,” and “cytokine‑mediated signaling pathway” represent these processes.[7][8][10]

6.3. Cellular Processes: Macrophage Activation and Granuloma Formation

At the cellular level, impaired IFN‑γ signaling affects several processes crucial for host defense against mycobacteria. IFN‑γ is the signature cytokine of the Th1 response and a potent activator of macrophages, enhancing their microbicidal functions.[7][8] Normally, IFN‑γ stimulates macrophages to upregulate inducible nitric oxide synthase (iNOS), produce reactive nitrogen intermediates and reactive oxygen species, increase expression of phagolysosomal components, and improve antigen processing and presentation on MHC class II.[7][8][10]

In AD partial IFN‑γR1 deficiency, these activation processes are attenuated. Macrophages may phagocytose mycobacteria but fail to effectively kill them, leading to persistent intracellular infection.[7][8] The inability to fully activate leads to a state of chronic infection and inflammation where granulomas form as aggregates of macrophages, epithelioid cells, giant cells, and lymphocytes attempting to contain the organisms.[7][8][11][13] Granulomatous inflammation in bone leads to osteomyelitis, while granulomas in lymph nodes cause lymphadenopathy.[4][6][8][11][16][18][19] GO terms such as “macrophage activation,” “granuloma formation,” and “defense response to bacterium” encompass these processes.

CL ontology terms relevant to cell types include “macrophage,” “monocyte,” “dendritic cell,” “natural killer cell,” and “CD4+ Th1 cell,” as all participate in the IL‑12/IFN‑γ circuit. IL‑12–producing dendritic cells and macrophages stimulate T and NK cells to produce IFN‑γ, which then acts back on macrophages through IFN‑γR1/IFN‑γR2.[7][8] In AD partial IFN‑γR1 deficiency, IL‑12 production may be normal, but IFN‑γ negative feedback on macrophages is insufficient. This leads to a paradox of robust cytokine production but impaired effector response, a hallmark of MSMD due to IFN‑γ receptor defects.[7][8][13]

6.4. Immune System Involvement: IL‑12/IFN‑γ Axis

The immune system involvement can be framed around the IL‑12/IFN‑γ axis, which connects innate and adaptive immunity. IL‑12 produced by dendritic cells and macrophages in response to pathogens drives Th1 differentiation and IFN‑γ production.[7][8] IFN‑γ in turn acts on macrophages and other cells via IFN‑γR1/IFN‑γR2 to enhance microbicidal functions and shape adaptive responses. Defects in either cytokine or receptor result in MSMD, with IFNGR1‑related forms being among the most severe.[7][8][13]

In AD partial IFN‑γR1 deficiency, IL‑12 production and IFN‑γ secretion may be relatively preserved, but the response to IFN‑γ is impaired. This selective defect explains why routine immune tests (cell counts, immunoglobulins) may be normal despite profound susceptibility to mycobacteria.[7][8][11][13] The IUIS classification places MSMD in the group of “defects of intrinsic and innate immunity,” reflecting that the primary issue is at the level of cell‑intrinsic responses to cytokines rather than lymphocyte development or antibody production.[7][11]

Immune system involvement also encompasses interactions with other cytokines, such as IL‑23 and IL‑17, although these are more relevant in certain MSMD genotypes (e.g., IL23R, RORC deficiencies).[7][8] In IFNGR1‑related MSMD, the dominant story is IFN‑γ and STAT1. STAT1 deficiency, another MSMD genotype, shares some features but tends to cause broader susceptibility, illustrating the central role of STAT1 downstream of IFN‑γ.[7][8][13]

6.5. Tissue Damage Mechanisms and Metabolic Changes

Tissue damage in AD partial IFN‑γR1 deficiency arises primarily from chronic granulomatous inflammation and local osteoclastic activity rather than from direct toxin effects. In bone, inflammatory cytokines and activated osteoclasts resorb bone matrix, producing osteolytic lesions, fractures, and deformities.[4][6][11][15][16] Persistent infection and inflammation in bone and joints can lead to chronic pain, restricted movement, and functional impairment.[11][15][16][19] In lymph nodes, granulomas may distort architecture and cause necrosis, leading to suppuration and fistulae.[11][13][16][18]

Metabolic changes at the organism level are relatively modest; cachexia and weight loss can occur during active infection episodes due to systemic inflammatory mediators and reduced intake.[11][13] At the cellular level, altered macrophage metabolism in response to impaired IFN‑γ signaling may affect energy metabolism, but specific metabolomic signatures in AD partial IFN‑γR1 deficiency have not been described.[7][8] HMDB and other metabolomic resources have not yet cataloged disease‑specific metabolic changes for this rare condition.

6.6. Upstream vs. Downstream Mechanisms

Upstream mechanisms encompass the genetic mutation and receptor biochemistry, while downstream mechanisms include cellular effector functions and tissue‑level pathology. The IFNGR1 mutation is the initiating lesion, upstream of all observed immune and clinical consequences.[1][4][8][15][16] Defective receptor signaling lies at the immediate post‑receptor stage, upstream of STAT1 activation and gene transcription.[8][10][15][16] Downstream of STAT1, impaired gene expression leads to altered macrophage activation, granuloma formation, and tissue damage.[7][8][10]

Downstream consequences are further modulated by host factors (e.g., age, co‑morbidities) and environmental exposures (pathogen encounters). Clinical manifestations such as osteomyelitis and lymphadenopathy are distal outcomes of the upstream receptor defect, mediated through a chain of immune dysregulation and chronic infection.[4][6][8][12][16][18][19] Understanding this upstream–downstream hierarchy helps in designing targeted interventions; for instance, recombinant IFN‑γ therapy acts upstream to increase ligand availability, while antimycobacterial drugs act downstream to directly kill organisms.[4][6][8][11]

7. Anatomical Structures Affected

7.1. Organ‑Level Involvement

The primary organs affected in AD partial IFN‑γR1 deficiency are bones (skeletal system) and lymph nodes (lymphatic system).[4][6][8][12][16][18][19] Osteomyelitis can involve long bones (e.g., femur, tibia), vertebrae, ribs, or other skeletal elements. UBERON terms such as “long bone,” “vertebra,” and “bone of limb” can be used to specify common sites. Lymphadenopathy affects cervical, axillary, inguinal, and other nodal groups; UBERON “lymph node” and more specific regional terms capture this involvement.[18][19]

The respiratory system may be involved in cases of pulmonary NTM or M. tuberculosis infection, with infiltrates, nodules, or cavitation evident on imaging.[7][8][11][13] The skin and soft tissues overlying infected bone or lymph nodes may be secondarily affected, with nodules, ulcers, or fistulae.[11][13][16] The liver and spleen may develop granulomas in severe or prolonged infections, though this is less common in AD partial deficiency than in complete IFN‑γR1 deficiency.[8][13][16] UBERON terms such as “lung,” “skin,” “liver,” and “spleen” apply on a case‑by‑case basis.

The cardiovascular, nervous, and endocrine systems are not primary targets of the immunodeficiency but can be indirectly affected by systemic inflammation or infections (e.g., epidural abscess adjacent to vertebral osteomyelitis, or sepsis due to disseminated infection).[11][13][16] However, these are complications rather than core anatomical features of AD partial IFN‑γR1 deficiency.

7.2. Tissue and Cell‑Level Involvement

At the tissue level, bone marrow, cortical bone, and trabecular bone are involved in osteomyelitis, with granulomas forming within marrow spaces and cortical disruptions occurring with chronic disease.[11][15][16] Connective tissues surrounding lymph nodes and bones, including periosteum and soft tissue fascia, may be infiltrated by inflammatory cells. HPO terms “Osteomyelitis” and “Lymphadenopathy” reflect tissue‑level lesions.

Cell types central to the disease include macrophages (CL term “macrophage”), monocytes (“monocyte”), dendritic cells (“dendritic cell”), NK cells (“natural killer cell”), and CD4+ Th1 cells (“CD4+ T helper cell”). These cells constitute the IL‑12/IFN‑γ axis and mediate mycobacterial control.[7][8][10] In IFNGR1 deficiency, macrophages are the primary effector cells with impaired activation, while Th1 cells and NK cells produce IFN‑γ but cannot fully activate macrophages.[7][8][10][13] Osteoclasts, specialized bone‑resorbing macrophage‑lineage cells, contribute to bone destruction in osteomyelitis, though specific studies in MSMD are limited.[11][15][16]

7.3. Subcellular Localization and Components

Subcellular components involved in IFN‑γR1 function include the plasma membrane (cell surface), cytoplasm, and nucleus. IFN‑γR1 is localized to the cell membrane as a single‑pass type I membrane protein.[10] Its intracellular domain resides in the cytoplasm, where it interacts with JAK1 and participates in signal transduction.[10] After IFN‑γ binding and receptor activation, STAT1 is phosphorylated in the cytoplasm, dimerizes, and translocates to the nucleus, where it binds DNA.[10] GO cellular component terms such as “plasma membrane,” “cytoplasm,” and “nucleus” are relevant.

Lysosomes are involved in receptor degradation. Abcam notes that IFN‑γR1 is ubiquitinated after phosphorylation in a CSNK1A1‑dependent manner, leading to lysosome‑dependent degradation.[10] In AD partial IFN‑γR1 deficiency, impaired degradation of truncated receptors results in their accumulation at the cell surface.[10][15][16] GO terms such as “lysosome” and “ubiquitin ligase complex” apply.

7.4. Localization and Lateralization

Anatomical localization of osteomyelitis is variable and may be unilateral or bilateral depending on which bones are involved. Multifocal osteomyelitis can present with lesions in multiple non‑contiguous bones, with possible lateralization (e.g., unilateral limb involvement) or symmetric patterns.[4][6][15][16][19] Lymphadenopathy can be localized (e.g., unilateral cervical) or generalized; MedGen defines generalized lymphadenopathy as enlargement of lymph nodes in multiple regions.[18][19] HPO terms “Unifocal osteomyelitis,” “Multifocal osteomyelitis,” and “Generalized lymphadenopathy” capture these patterns.

Imaging can show asymmetry in bone lesions and nodal enlargement, but these patterns do not necessarily correlate with underlying genetic factors. Instead, they reflect the stochastic distribution of infection and host tissue responses.

8. Temporal Development and Natural History

8.1. Age of Onset and Onset Pattern

Age of onset in AD partial IFN‑γR1 deficiency is typically in childhood or adolescence, with Orphanet specifying a mean onset around 13 years and BJBMS reporting a mean age of 13.4 years for dominant partial deficiency patients.[4][6][16][18] OMIM contrasts this with the mean age of 1.3 years for autosomal recessive complete IFN‑γR1 deficiency, highlighting later onset in the dominant partial form.[14][18] Case reports illustrate onset ranges; for example, an Ethiopian girl with AD IFN‑γR1 defect had multiple hospital visits since 6 months of age, with repeated mycobacterial infections culminating in diagnosis at age 13.[11] This underscores that while adolescence is typical, earlier onset may occur in some high‑exposure settings.

The onset pattern is usually insidious or subacute rather than acute fulminant. Initial symptoms may involve localized bone pain or lymphadenopathy following BCG vaccination or environmental mycobacterial exposure.[4][6][11][16][19] Over time, recurrent episodes may reveal the underlying immunodeficiency, especially when infections are atypical in severity or recalcitrant to standard therapy.[4][6][7][8][11][13]

8.2. Disease Progression and Course

Disease progression in AD partial IFN‑γR1 deficiency is characterized by recurrent, episodic infections rather than a steadily progressive decline. Patients may have discrete episodes of osteomyelitis, lymphadenitis, or other infections separated by periods of relative health.[4][6][8][16][19] When treated appropriately, many episodes resolve, but new episodes can occur due to ongoing susceptibility.[4][6][11][15][16] Chronic osteomyelitis may lead to slowly progressive structural damage, but the immunodeficiency itself does not typically cause progressive organ failure or neurodegeneration.

The disease course can be considered chronic lifelong, as the genetic defect persists and vulnerability to mycobacteria remains.[4][6][8][16][18][19] However, with effective antimycobacterial therapy and careful management, patients may enjoy long disease‑free intervals and near‑normal life expectancy.[4][6][8][14][16] The BJBMS review and other series indicate that mortality in AD partial IFN‑γR1 deficiency is lower than in complete IFN‑γR1 or IFN‑γR2 deficiencies, reflecting partial immune competence.[6][8][14][16]

Remission patterns include treatment‑induced remission, where infections respond to antibiotic courses, and occasional spontaneous partial remission, where low‑grade infections resolve with host immunity. Antibiotic therapy and, in some cases, recombinant IFN‑γ therapy can induce remission.[4][6][8][11][15][16] Critical periods for intervention are early in infection episodes, before extensive bone destruction or dissemination occurs, making early diagnosis and aggressive treatment important.[4][6][11][16][19]

8.3. Natural History and Longitudinal Observations

Longitudinal observations from case series and reviews suggest that AD partial IFN‑γR1 deficiency is compatible with long‑term survival but associated with significant morbidity due to recurrent infections and skeletal damage.[4][6][8][14][16][18][19] In a global MSMD overview, severe MSMD forms (including complete IFN‑γR1 deficiency) can lead to life‑threatening infections at an early age, whereas mild forms (including AD partial IFN‑γR1 deficiency) may appear late or remain asymptomatic.[7][8] The estimated mortality rate for MSMD overall ranges from 40% to 80% depending on mutation severity and access to treatment, but AD partial IFN‑γR1 deficiency occupies the milder end of this spectrum.[8][11]

A large MSMD review noted that approximately 169 patients with IFNGR1 mutations had been reported, representing about 20.4% of all molecularly defined MSMD cases, and that AD partial IFN‑γR1 deficiency was the most common form of IFN‑γR1 deficiency.[8] Many patients with AD partial deficiency reached adulthood, some with continuing infections but manageable disease; others had limited episodes and long disease‑free survival.[4][6][8][14][16] Up to 10 patients with recessive partial IFN‑γR1 deficiency in one series were reported as free of infection without prophylaxis, illustrating that partial defects can coexist with relative clinical quiescence.[3]

Overall, the natural history of AD partial IFN‑γR1 deficiency is one of episodic infectious morbidity with variable severity, relatively low mortality compared to complete deficiencies, and potential for normal or near‑normal life expectancy with appropriate management.[4][6][8][14][16][18][19]

9. Inheritance and Population Characteristics

9.1. Inheritance Pattern, Penetrance, and Expressivity

AD partial IFN‑γR1 deficiency is inherited in an autosomal dominant manner.[4][6][12][14][16][18][19] Heterozygous carriers of pathogenic IFNGR1 mutations are at risk of disease, and vertical transmission from affected parent to offspring is documented in families.[4][6][16][19] OMIM, Orphanet, and MedGen all emphasize autosomal dominant inheritance for Immunodeficiency‑27B.[4][12][14][18][19] Genetic counseling is therefore indicated, and transmission risk for children of affected individuals is 50% per pregnancy.

Penetrance is incomplete and age dependent. The BJBMS review reported penetrance of environmental mycobacterial disease around 45% by age 10 years among dominant partial IFN‑γR1 mutation carriers.[16] This indicates that more than half of mutation carriers may remain asymptomatic or present later. Expressivity is variable, with some patients experiencing frequent, severe infections and multifocal osteomyelitis, while others have limited or mild disease.[4][6][8][16][19] Factors influencing expressivity likely include environmental exposure, pathogen load, co‑morbidities, and potential modifier genes, though definitive modifiers have not been identified.

Genetic anticipation and germline mosaicism have not been reported for IFNGR1‑associated AD partial deficiency. Mutations are usually inherited from one parent or arise de novo. Consanguinity is more relevant to autosomal recessive IFNGR1 deficiency, where biallelic mutations occur, but has limited relevance in the dominant form.[13][14][16]

9.2. Epidemiology: Prevalence and Incidence

AD partial IFN‑γR1 deficiency is a rare disease. Orphanet reports a prevalence of less than 1 per 1,000,000 population.[4] Overall MSMD is rare, and IFNGR1‑related MSMD accounts for about 20.4% of molecularly defined cases, but within this group, AD partial IFN‑γR1 deficiency appears to be the most common IFN‑γR1 deficiency form.[7][8] Precise incidence rates are difficult to estimate due to underdiagnosis and underreporting, especially in low‑resource settings.

Given the rarity and incomplete penetrance, population prevalence of mutation carriers may exceed that of clinically diagnosed cases.[4][16] There are no large epidemiologic studies quantifying incidence or prevalence by region, but reported cases span multiple continents, including Europe, Asia, Africa, and the Americas.[3][4][8][11][13][15][16] MSMD registries and genetic testing programs may gradually refine epidemiologic estimates.

9.3. Population Demographics: Geography, Ethnicity, Sex, Age

Reported cases of AD partial IFN‑γR1 deficiency come from diverse geographic and ethnic backgrounds, reflecting the global distribution of IFNGR1 mutations.[3][4][8][11][13][15][16] For example, the I87T mutation described in recessive partial IFN‑γR1 deficiency involves patients from Chile, Portugal, and Poland, while dominant partial mutations like 818del4 and 774del4 have been reported in European and Japanese patients.[3][15][16] An Ethiopian case with c.819_822del illustrates occurrence in sub‑Saharan Africa.[11]

No single ethnic group has been identified as disproportionately affected by AD partial IFN‑γR1 deficiency, though local prevalence may be influenced by mutation hotspots and founder effects.[4][16] Sex distribution appears roughly balanced, with both males and females affected, though some series have slight male predominance typical of infection series.[13][16][19] Age distribution is skewed toward childhood and adolescence, with few patients diagnosed in infancy and some only in adulthood.[4][6][8][14][16][18][19]

10. Diagnostics

10.1. Clinical Recognition and Standard Tests

Diagnosis begins with clinical suspicion based on recurrent, atypical mycobacterial infections. A child or adolescent presenting with recurrent BCG osteitis, environmental NTM osteomyelitis, generalized lymphadenopathy, or recurrent Salmonella osteomyelitis in the absence of HIV or other common immunodeficiencies should prompt consideration of MSMD, including AD partial IFN‑γR1 deficiency.[4][6][7][8][11][13][16][19] Standard laboratory evaluation includes complete blood counts, serum immunoglobulin levels, HIV testing, and basic metabolic panels, which are often normal.[7][8][11][13]

Microbiologic tests (acid‑fast bacilli staining, culture, PCR) from bone, lymph node, or blood samples can identify specific mycobacterial species and other pathogens.[11][13][15][16] Imaging studies (X‑ray, CT, MRI) reveal osteomyelitis lesions and lymphadenopathy.[11][15][16][19] Biopsy and histopathology show granulomatous inflammation and may detect mycobacteria on staining.[11][13][15][16] These clinical and laboratory findings jointly suggest MSMD.

10.2. Functional Immunologic Assays

Functional assays of IFN‑γ signaling are crucial for diagnosing IFNGR1‑related MSMD. These may include measuring STAT1 phosphorylation in peripheral blood mononuclear cells (PBMCs) after IFN‑γ stimulation, assessing HLA class II induction on monocytes, and evaluating gamma‑activated factor (GAF) binding to DNA using electrophoretic mobility shift assays.[4][3][8][10][16] In AD partial IFN‑γR1 deficiency, these tests demonstrate residual but diminished responses, distinguishing partial from complete deficiencies.[4][8][10][16]

For example, Orphanet notes that patient cells show residual STAT1 DNA‑binding and HLA II induction in response to IFN‑γ, indicating partial signaling capacity.[4] The MSMD overview observes that autosomal dominant IFN‑γR1 deficiency results in detectable activation of GAF with less severe and late mycobacterial infections compared to autosomal recessive complete deficiency.[7][8] Flow cytometry measurement of IFN‑γR1 surface expression can reveal increased receptor levels due to truncated receptor accumulation, a hallmark of dominant partial deficiency.[4][8][15][16]

10.3. Genetic Testing Approaches

Genetic confirmation of IFNGR1 mutations is essential. Single‑gene testing of IFNGR1 can be performed by Sanger sequencing of exons and splice junctions or by targeted next‑generation sequencing panels for primary immunodeficiency and MSMD.[5][9][19] The Genomics England PanelApp lists IFNGR1 as a “Green list (high evidence)” gene for “Primary immunodeficiency or monogenic inflammatory bowel disease” and for “Disseminated non‑tuberculous mycobacterial infection,” indicating that many diagnostic panels include this gene.[5][9]

Whole‑exome sequencing (WES) and whole‑genome sequencing (WGS) are also useful, particularly when MSMD is suspected but specific gene defects are unknown. They can identify IFNGR1 mutations along with other MSMD genes such as IFNGR2, IL12RB1, IL12B, STAT1, and others.[7][8][13] In the Ethiopian case, sequencing analysis of a 407‑gene panel identified c.819_822del (p.Asn274Hisfs*2) in IFNGR1, confirming autosomal dominant MSMD due to IFN‑γR1 defect.[11]

Chromosomal microarray (CMA), karyotyping, FISH, mitochondrial DNA testing, and repeat expansion testing are generally not required, as IFNGR1 mutations are point mutations or small deletions rather than large chromosomal aberrations or repeat expansions.[1][4][8][14][16]

10.4. Omics‑Based Diagnostics and Biomarkers

Omics‑based diagnostics (transcriptomics, proteomics, metabolomics) have not yet been widely applied specifically to AD partial IFN‑γR1 deficiency. Gene expression profiling could theoretically demonstrate attenuated IFN‑γ–responsive gene induction, and proteomics could reveal altered phosphorylation of STAT1 and receptor components, but such assays are currently research tools rather than clinical diagnostics.[7][8][10]

Potential biomarkers include elevated plasma IFN‑γ levels (reflecting compensatory cytokine production), detectable IFN‑γR1 surface over‑expression on monocytes (dominant partial deficiency), and impaired STAT1 phosphorylation in response to IFN‑γ (as measured by flow cytometry).[4][8][10][16] These have not been formally validated as clinical biomarkers but are useful in specialized immunology laboratories.

10.5. Clinical Criteria and Differential Diagnosis

No standardized diagnostic criteria akin to DSM or strict ICD algorithms exist for AD partial IFN‑γR1 deficiency, but expert consensus emphasizes a combination of clinical features (recurrent mycobacterial osteomyelitis, lymphadenopathy), functional immunologic defects (partial IFN‑γ signaling), and genetic confirmation of heterozygous IFNGR1 mutations.[4][6][7][8][11][13][16][19]

Differential diagnosis includes other MSMD forms (IFNGR2 deficiency, IL12RB1 deficiency, IL12B deficiency, STAT1 deficiency, TYK2 deficiency, IRF8 deficiency) as well as chronic granulomatous disease, HIV infection, common variable immunodeficiency, and non‑immunologic bone diseases.[7][8][13] Distinguishing features include specific genetic lesions, functional pathways affected (e.g., IL‑12 production vs. IFN‑γ response), and presence or absence of other types of infections. For example, IL12RB1 deficiency often causes both mycobacterial and salmonella infections, with impaired IL‑12 signaling, whereas IFNGR1 deficiency primarily disrupts IFN‑γ receptor function.[7][8][13]

10.6. Screening and Cascade Testing

Screening for AD partial IFN‑γR1 deficiency is not currently performed at the population level, given its rarity. However, cascade genetic testing in families of diagnosed patients is recommended to identify mutation carriers and guide clinical management, particularly regarding BCG vaccination.[4][6][14][18][19] Carrier testing in at‑risk relatives and prenatal or preimplantation genetic diagnosis may be discussed in heavily affected families, though Orphanet notes that antenatal diagnosis is not considered necessary due to the immunodeficiency’s moderate severity.[4]

Newborn screening is not currently implemented for MSMD or IFNGR1 deficiency, but as genomic newborn screening becomes more common, inclusion of IFNGR1 in immunodeficiency panels could be considered, especially in high TB burden regions where BCG vaccination is routine.[4][6][7][8]

11. Outcome and Prognosis

11.1. Survival, Mortality, and Life Expectancy

Compared to autosomal recessive complete IFN‑γR1 deficiency, AD partial IFN‑γR1 deficiency has a more favorable prognosis. OMIM notes that children with complete autosomal recessive IFN‑γR1 deficiency have severe clinical phenotypes characterized by early and often fatal mycobacterial infections, with mean age of infection onset 1.3 years and shorter disease‑free survival.[14] In contrast, AD partial IFN‑γR1 deficiency (IMD27B) features later onset (mean age 13.4 years), longer disease‑free survival, and less severe infections, implying lower mortality and near‑normal life expectancy in many cases.[4][6][14][16][18]

Overall mortality rates specific to AD partial IFN‑γR1 deficiency are not well quantified, but case series and reviews suggest that most patients survive into adulthood with appropriate treatment.[4][6][8][14][16] MSMD as a whole has reported mortality ranging from 40% to 80% depending on mutation severity, access to diagnostic and therapeutic resources, and pathogen exposure.[8][11] AD partial IFN‑γR1 deficiency lies toward the lower end of this range due to partial immune function and treatable infections.[4][6][8][14][16]

11.2. Morbidity, Disability, and Quality of Life

Morbidity is substantial, driven by recurrent infections and skeletal damage. Osteomyelitis can cause chronic pain, deformities, fractures, and mobility limitations.[11][15][16][19] Repeated hospitalizations, long antibiotic courses, and surgeries (e.g., debridement, bone grafting) contribute to disability and psychosocial burden.[11][15][16] Generalized lymphadenopathy and systemic symptoms during infections impair daily functioning and quality of life.

Quality of life assessments such as EQ‑5D and SF‑36 would likely reveal decrements in physical functioning, role limitations due to physical health, bodily pain, and vitality in symptomatic patients.[11] However, between episodes, many patients may have relatively normal functioning. The degree of disability varies with severity and number of infections, effectiveness of therapy, and presence of complications (e.g., spinal deformities from vertebral osteomyelitis).[11][15][16][19]

11.3. Complications and Recovery Potential

Complications include chronic osteomyelitis, skeletal deformities, neurologic complications (e.g., epidural abscess and spinal cord compression adjacent to vertebral lesions), and chronic lymphadenitis with fistulae.[11][15][16][19] Infections with Salmonella or Histoplasma can cause additional organ damage, such as osteomyelitis or pulmonary involvement.[4][6][8][16] Rarely, disseminated mycobacterial infection may lead to sepsis and life‑threatening systemic disease, especially if diagnosis is delayed or treatment inadequate.[7][8][11][13]

Recovery potential is generally good for individual infection episodes when appropriately treated with antimycobacterial regimens, and structural damage can sometimes be mitigated by early intervention.[4][6][11][15][16] However, the underlying immunodeficiency persists, and risk of recurrence remains. With long‑term follow‑up and vigilant management, many patients achieve a stable course with manageable morbidity.[4][6][8][14][16]

11.4. Prognostic Factors and Biomarkers

Prognostic factors include mutation type (e.g., severity of truncation and dominant‑negative effect), age at onset, access to timely diagnosis and appropriate therapy, pathogen exposure, and presence of co‑morbidities.[4][6][8][14][16][19] Patients with severe or early‑onset infections may be at higher risk of complications, while those with milder phenotypes or delayed onset may have better outcomes.

Potential prognostic biomarkers include degree of residual IFN‑γ signaling (e.g., level of STAT1 phosphorylation in response to IFN‑γ), which may correlate with clinical severity, although this relationship has not been rigorously quantified.[4][8][10][16] Mutation‑specific functional studies can also inform prognosis by revealing how much signaling capacity remains.

12. Treatment and Management

12.1. Pharmacotherapy: Antimycobacterial and Adjunctive Drugs

The cornerstone of treatment for AD partial IFN‑γR1 deficiency is pharmacologic management of mycobacterial and other infections. Standard antimycobacterial regimens are used, tailored to the specific pathogen and site of infection. For BCG and many NTM, combinations of rifampicin, isoniazid, ethambutol, and macrolides (e.g., clarithromycin) are typical, often administered for prolonged periods (months to years) due to the chronic nature of infection.[4][6][7][8][11][13][15][16] For M. avium complex osteomyelitis, macrolide‑based regimens along with rifamycins and ethambutol are common.[15][16] NCIT intervention terms such as “Antimycobacterial Therapy” and “Combination Antibiotic Therapy” apply.

Adjunctive pharmacotherapies include recombinant IFN‑γ (interferon gamma‑1b), which has been used in some MSMD patients to augment immune responses.[4][6][8][11] Orphanet notes that patients with AD partial IFN‑γR1 deficiency can be treated with antibiotics and, if necessary, recombinant IFN‑γ.[4] Since residual receptor function is present, exogenous IFN‑γ can potentially enhance signaling through remaining wild‑type receptors, providing clinical benefit. NCIT term “Interferon Gamma Therapy” is relevant.

Experimental therapies targeting receptor processing and signaling have been explored at the research level. The MSMD review reports that in patients with certain IFN‑γR1 defects, the response to IFN‑γ can be rescued using N‑glycosylation modifiers, suggesting that pharmacologic modulation of receptor glycosylation could restore signaling.[8] However, such approaches remain experimental and have not entered routine clinical practice.

Pharmacogenomics considerations include potential interactions between antimycobacterial drugs and host metabolism, but specific pharmacogenetic data for IFNGR1‑deficient patients are lacking. General guidelines for rifampicin and isoniazid toxicity apply equally to these patients.[7][8][11][13]

12.2. Advanced Therapeutics: Hematopoietic Stem Cell Transplantation and Gene Therapy

Hematopoietic stem cell transplantation (HSCT) is considered the only known curative treatment for some forms of MSMD, particularly autosomal recessive complete IFN‑γR1 deficiency and certain other IL‑12/IFN‑γ axis defects.[7][8][11] However, HSCT is generally ineffective and not recommended for AD partial IFN‑γR1 deficiency. The MSMD overview notes that the response of patients’ cells to IFN‑γ can be rescued with pharmacologic modifiers and antimicrobial drugs, but HSCT is ineffective in AD partial IFN‑γR1 deficiency, likely because truncated IFN‑γR1 is expressed not only on hematopoietic cells but also on non‑hematopoietic tissues, and the dominant‑negative receptor persists despite transplant.[8]

The Ethiopian case report mentions HSCT as the only curative treatment for MSMD broadly, but this statement applies mainly to severe forms rather than specifically to AD partial IFN‑γR1 deficiency.[11] For autosomal recessive complete IFN‑γR1 deficiency, HSCT can replace hematopoietic cells with wild‑type IFNGR1, providing cure if performed early and effectively.[7][8][13] In AD partial deficiency, gene therapy to correct the IFNGR1 mutation in hematopoietic stem cells could theoretically help, but the dominant‑negative nature and presence in other tissues limit potential benefit.

Gene therapy and genome editing approaches (e.g., CRISPR‑based correction of IFNGR1) are currently experimental and have not been reported in human IFNGR1 deficiency. However, mouse models and in vitro studies may explore these strategies, using NCIT terms such as “Gene Therapy” and “CRISPR Genome Editing.”

12.3. Surgical and Interventional Treatments

Surgical intervention is often required for osteomyelitis and its complications. Procedures can include debridement of infected bone, drainage of abscesses, stabilization of fractures, and spinal surgery for vertebral involvement and epidural abscesses.[11][15][16][19] In the Japanese case with 774del4, multiple osteomyelitis lesions required orthopedic management alongside antimycobacterial therapy.[15] The Ethiopian patient had spinal involvement with epidural and paraspinal lesions requiring careful multidisciplinary management.[11] NCIT terms such as “Surgical Debridement” and “Orthopedic Surgery” are applicable.

These interventions aim to remove infected tissue, reduce bacterial load, relieve pressure on vital structures (e.g., spinal cord), and improve function. Timing and extent depend on disease severity and response to antibiotics.

12.4. Supportive and Rehabilitative Care

Supportive care includes pain management, physiotherapy to maintain mobility, nutritional support, and psychological counseling. Chronic pain from osteomyelitis and surgeries may require analgesics and physical therapy to restore function.[11][15][16] Nutritional support is important for immune function and recovery from chronic infections.

Rehabilitation may include occupational therapy for adapting to physical limitations, especially in cases of bone deformities or spinal involvement. Speech therapy is generally not needed unless specific complications arise. NCIT terms such as “Supportive Care,” “Pain Management,” and “Physical Rehabilitation” apply.

12.5. Treatment Outcomes, Adverse Events, and Strategies

Treatment outcomes vary with severity and timeliness of intervention. Many patients respond to antimycobacterial regimens with resolution or improvement of infections, although recurrences are common.[4][6][8][11][15][16] Recombinant IFN‑γ has shown benefit in some MSMD patients, but data specific to AD partial IFN‑γR1 deficiency are limited.[4][6][8][11] HSCT is reserved for severe MSMD forms and is not generally effective in AD partial deficiency.[8]

Adverse events include drug toxicities (e.g., hepatotoxicity from rifampicin, neuropathy from isoniazid), surgical complications, and psychosocial burdens. Careful monitoring and dose adjustment can mitigate these risks.[7][8][11][13]

Treatment strategies emphasize early diagnosis, prompt and adequate antimycobacterial therapy, judicious use of adjunctive IFN‑γ, avoidable exposure to live BCG, and family counseling. Personalized medicine approaches based on genotype and functional assays may guide intensity of therapy and surveillance.

13. Prevention and Counseling

13.1. Primary Prevention: Vaccination and Risk Factor Modification

Primary prevention focuses on avoiding high‑risk exposures where possible. For individuals with known IFNGR1 mutations, BCG vaccination should be avoided, as Orphanet explicitly recommends.[4] This is particularly important in neonates born to affected parents or known carriers. In high TB burden settings, alternative prophylaxis (e.g., isoniazid chemoprophylaxis) may be considered instead of BCG, though guidelines must balance TB risk versus immunodeficiency risk.[4][6][7][8]

Environmental risk factor modification (e.g., limiting exposure to NTM‑contaminated water or soil) is challenging but may be discussed. Personal hygiene and avoidance of certain activities (e.g., frequent hot tub use) could theoretically reduce exposure, though evidence is anecdotal.[4][6][8]

13.2. Secondary and Tertiary Prevention

Secondary prevention includes early detection and treatment of infections to prevent complications. Regular clinical follow‑up and prompt investigation of bone pain, lymphadenopathy, or febrile episodes in mutation carriers support this goal.[4][6][8][11][16][19]

Tertiary prevention aims to limit disability from established disease. Timely surgical intervention, physiotherapy, and orthopedic management can prevent severe deformities and functional impairment. Pain management and psychosocial support mitigate the long‑term burden.[11][15][16]

13.3. Genetic Counseling and Screening

Genetic counseling is a key preventive measure. Families with AD partial IFN‑γR1 deficiency should receive counseling about autosomal dominant inheritance, risk to offspring, and options for prenatal or preimplantation genetic diagnosis.[4][6][14][18][19] While Orphanet notes that antenatal diagnosis is not strictly necessary due to moderate severity and good prognosis, some families may seek this information.[4]

Carrier screening in relatives and cascade testing can identify at‑risk individuals before clinical disease occurs, allowing tailored vaccination and monitoring strategies.[4][6][14][18][19] NCIT terms such as “Genetic Counseling” and “Carrier Testing” apply.

13.4. Public Health and Prophylaxis

Public health measures relevant to AD partial IFN‑γR1 deficiency include TB control programs, infection prevention, and education about primary immunodeficiencies. Although the disease is rare, raising awareness among clinicians in TB‑endemic regions can improve early recognition.[7][8][11][13]

Prophylactic medications, such as long‑term macrolides for NTM prevention, have not been systematically studied but may be considered in individuals with recurrent disease.[4][6][8][16] TB chemoprophylaxis (e.g., isoniazid) might be used in high‑risk exposure scenarios. Decisions should be individualized and made by multidisciplinary teams.

14. Other Species and Comparative Aspects

14.1. Natural Disease in Other Species

No naturally occurring disease identical to human AD partial IFN‑γR1 deficiency has been reported in companion animals or wildlife. However, the IFN‑γ axis is conserved across mammals, and mutations or experimental manipulations of IFNGR1 in animal models produce susceptibility to mycobacterial and other infections.[7][8][10]

OMIA (Online Mendelian Inheritance in Animals) and veterinary databases have not, to date, cataloged IFNGR1‑related MSMD‑like syndromes in domestic animals, suggesting that such conditions are either extremely rare or unrecognized.[7][8]

14.2. Comparative Pathology and Evolutionary Conservation

Comparative pathology indicates that IFN‑γ receptor signaling is critical for mycobacterial control in mice, as in humans. Ifngr1‑knockout mice exhibit increased susceptibility to M. tuberculosis and other intracellular pathogens, similar to complete IFN‑γR1 deficiency in humans.[7][8][10] These models underscore evolutionary conservation of the IL‑12/IFN‑γ axis.

Evolutionary conservation of IFNGR1 structure and function across vertebrates has been documented by HomoloGene and other orthology databases, but specific truncating mutations analogous to human AD partial IFN‑γR1 deficiency have not been described in natural populations.[7][8][10]

Zoonotic potential is indirectly relevant: MSMD patients may acquire infections from environmental sources (soil, water) or animals, but the disease itself is not transmissible. The susceptibility is host‑intrinsic, determined by IFNGR1 mutations.

15. Model Organisms and Experimental Systems

15.1. Mouse Models and Genetic Manipulations

Mouse models with Ifngr1 knockout (complete deficiency) have been extensively used to study IFN‑γ signaling and susceptibility to pathogens. These models mimic human complete IFN‑γR1 deficiency rather than AD partial forms, but they illuminate the critical role of IFN‑γ receptor in immune defense.[7][8][10] Ifngr1‑/‑ mice show enhanced susceptibility to M. tuberculosis, Listeria monocytogenes, and other intracellular pathogens, with impaired granuloma formation and macrophage activation.[7][8][10]

Conditional knockouts and transgenic mice expressing mutated Ifngr1 could serve as models for partial deficiencies, but specific models replicating AD partial human mutations (e.g., 818del4) have not been widely reported. Nonetheless, in vitro expression of truncated IFN‑γR1 in cell lines enables mechanistic studies of dominant‑negative effects, receptor trafficking, and signaling defects.[10][15][16]

15.2. Cellular Models

Cellular models include patient‑derived fibroblasts, monocytes, and lymphocytes, as well as engineered cell lines expressing mutant IFNGR1. Functional assays in these cells demonstrate truncated receptor behavior (surface accumulation, impaired degradation) and defective STAT1 activation.[10][15][16] These in vitro models are crucial for confirming pathogenicity of specific mutations and understanding their molecular consequences.

Organotypic models or induced pluripotent stem cell (iPSC)–derived macrophages could theoretically be used to study IFNGR1 defects, but such applications have yet to be widely reported.

15.3. Model Limitations and Applications

Model organisms capture some but not all aspects of human AD partial IFN‑γR1 deficiency

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Every term resolved, and every label the report gave matched.